Results 141 to 150 of about 1,481 (180)

Variables associated with response to Esketamine nasal spray treatment in clinical practice: Integrate study

Neuroscience Applied
P. Molero, A. Ibañez, J. de Diego, J.A. Ramos-Quiroga, P.M. López, P.A. Saiz   +5 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

New England Journal of Medicine, 2023
In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation ...
Reif, Andreas, Bitter, Istvan, Buyze, Jozefien, Cebulla, Kerstin, Frey, Richard, Fu, Dong-Jing, Ito, Tetsuro, Kambarov, Yerkebulan, Llorca, Pierre-Michel, Oliveira-Maia, Albino J., Messer, Thomas, Mulhern-Haughey, Siobhán, Rive, Benoît, von Holt, Christian, Young, Allan H., Godinov, Yordan, Normann, Claus, Thiel, Nicola, Hamoudi, Manuela, Frase, Lukas, Paulus, Jan, Vestring, Stefan   +21 more
openaire   +5 more sources

Esketamine Nasal Spray Effective in Treatment-Resistant Depression

JAMA, 2019
openaire   +4 more sources

Longer course of esketamine nasal spray benefits initial treatment nonresponders

The Brown University Psychopharmacology Update, 2021
Extending adjunctive treatment with esketamine nasal spray over 4 weeks showed benefit in a group of patients with treatment‐resistant depression who did not respond within the first week of treatment, a post hoc analysis of two Phase 3 studies has found.
openaire   +1 more source

Sustained improvement in depression seen in study of esketamine nasal spray

The Brown University Psychopharmacology Update, 2023
Interim results from a Phase 3 study of esketamine nasal spray in patients with treatment‐resistant depression showed no emerging safety concerns and sustained improvement in depressive symptoms. Nearly half of study participants met criteria for remission at the end of the study's optimization/maintenance phase, the investigators reported.
openaire   +1 more source

Esketamine nasal spray offers rapid improvement in treatment‐resistant depression

The Brown University Psychopharmacology Update, 2019
Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for ...
openaire   +1 more source

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

The Journal of Clinical Psychiatry
Background: Under a risk evaluation and mitigation strategy program, esketamine nasal spray CIII requires self administration at a certified treatment center. Our objective was to identify factors associated with esketamine initiation and continuation.Methods: A retrospective observational cohort study was conducted among US adults who met treatment ...
Kruti, Joshi, Joshua N, Liberman, Purva, Parab, Jonathan D, Darer, Lisa, Harding   +4 more
openaire   +2 more sources

Esketamine nasal spray offers rapid benefit in patients at risk of suicide

The Brown University Psychopharmacology Update, 2020
Esketamine nasal spray acted rapidly to reduce depressive symptoms in a 4‐week study of patients with major depressive disorder and active suicidal ideation with intent. The results offer promise for emergency treatment of a condition for which there is currently no approved therapeutic.
openaire   +1 more source